Skip to main content
SpringerLink
Log in

Anti-tumor Necrosis Factor-Alpha Agents

  • Chapter
  • First Online:
Infectious Complications in Biologic and Targeted Therapies

  • 346 Accesses

Abstract

Tumor necrosis factor-α (TNF-α) plays a central role in the immunopathogenesis of a wide variety of inflammatory conditions from diseases such as rheumatoid arthritis to inflammatory bowel diseases. Development of TNF-α inhibitors (TNFI) has revolutionized the ability to treat these conditions, resulting in substantial improvement in clinical outcomes. Since the introduction of infliximab and etanercept in 1998, indications for the use of TNFI have expanded, and these medications are predominately prescribed by rheumatologists, dermatologists, and gastroenterologists for moderate to severe inflammatory and autoimmune diseases. As a result of widespread use of these effective therapies, there have been safety concerns related to immunosuppression, the foremost of which is the increased incidence of infections caused by a broad range of pathogens. In this chapter, we review available data on the epidemiology of infectious complications in patients receiving TNFI for the treatment of inflammatory conditions.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–9.

    Article  CAS  PubMed  Google Scholar 

  2. Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, Nordström DC, Blom M. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One. 2012;7(1):e30275.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Corbett M, Soares M, Jhuti G, Rice S, Spackman E, Sideris E, et al. Tumour necrosis factor-α inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation. Health Technol Assess (Rockv). 2016;20(9):333.

    Google Scholar 

  4. Baddley JW, Cantini F, Goletti D, Gómez-Reino JJ, Mylonakis E, San-Juan R, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents). Clin Microbiol Infect. 2018;24:S10–20.

    Article  CAS  PubMed  Google Scholar 

  5. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-∅ from cells. Nature. 1997;385(6618):729–33.

    Article  CAS  PubMed  Google Scholar 

  6. Walczak H. TNF and ubiquitin at the crossroads of gene activation, cell death, inflammation, and cancer. Immunol Rev. 2011;244(1):9–28.

    Article  CAS  PubMed  Google Scholar 

  7. Billmeier U, Dieterich W, Neurath MF, Atreya R. Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases. World J Gastroenterol. 2016;22(42):9300–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Kaushansky K, Broudy VC, Harlan JM, Adamson JW. Tumor necrosis factor-γ and tumor necrosis factor-β (lymphotoxin) stimulate the production of granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, and IL-1 in vivo. J Immunol. 1988;141(10):3410–5.

    CAS  PubMed  Google Scholar 

  9. Shalaby MR, Aggarwal BB, Rinderknecht E, Svedersky LP, Finkle BS, Palladino MA. Activation of human polymorphonuclear neutrophil functions by interferon-gamma and tumor necrosis factors. J Immunol. 1985;135(3):2069–73. http://www.ncbi.nlm.nih.gov/pubmed/3926894.

    CAS  PubMed  Google Scholar 

  10. Sumagin R, Sarelius IH. TNF-α activation of arterioles and venules alters distribution and levels of ICAM-1 and affects leukocyte-endothelial cell interactions. Am J Physiol Heart Circ Physiol. 2006;291(5):H2116.

    Article  CAS  PubMed  Google Scholar 

  11. Murao K, Ohyama T, Imachi H, Ishida T, Cao WM, Namihira H, et al. TNF-α stimulation of MCP-1 expression is mediated by the Akt/PKB signal transduction pathway in vascular endothelial cells. Biochem Biophys Res Commun. 2000;276(2):791–6.

    Article  CAS  PubMed  Google Scholar 

  12. Victor FC, Gottlieb AB. TNF-alpha and apoptosis: implications for the pathogenesis and treatment of psoriasis. J Drugs Dermatol. 2002;1:264–75.

    PubMed  Google Scholar 

  13. Roach DR, Bean AGD, Demangel C, France MP, Briscoe H, Britton WJ. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol. 2002;168(9):4620–7.

    Article  CAS  PubMed  Google Scholar 

  14. Marino MW, Dunn A, Grail D, Inglese M, Noguchi Y, Richards E, et al. Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci U S A. 1997;94(15):8093–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Flynn JAL, Goldstein MM, Chan J, Triebold KJ, Pfeffer K, Lowenstein CJ, et al. Tumor necrosis factor-α is required in the protective immune response against mycobacterium tuberculosis in mice. Immunity. 1995;2(6):561–72.

    Article  CAS  PubMed  Google Scholar 

  16. Resende M, Cardoso MS, Fróis-Martins R, Borges M, Jordan MB, Castro AG, et al. TNF-mediated compensatory immunity to Mycobacterium avium in the absence of macrophage activation by IFN-γ. J Immunol. 2019;203(9):2451–8.

    Article  CAS  PubMed  Google Scholar 

  17. Zhou P, Miller G, Seder RA. Factors involved in regulating primary and secondary immunity to infection with Histoplasma capsulatum: TNF-alpha plays a critical role in maintaining secondary immunity in the absence of IFN-gamma. J Immunol. 1998;160(3):1359–68. http://www.ncbi.nlm.nih.gov/pubmed/9570555.

    CAS  PubMed  Google Scholar 

  18. Mehrad B, Strieter RM, Standiford TJ. Role of TNF-alpha in pulmonary host defense in murine invasive aspergillosis. J Immunol. 1999;162(3):1633–40.

    CAS  PubMed  Google Scholar 

  19. Huffnagle GB, Toews GB, Burdick MD, Boyd MB, McAllister KS, McDonald RA, et al. Afferent phase production of TNF-α is required for the development of protective T cell immunity to Cryptococcus neoformans. J Immunol. 1996;157(10):4529–36.

    CAS  PubMed  Google Scholar 

  20. Lemos LLP, de Oliveira Costa J, Almeida AM, Junior HO, Barbosa MM, Kakehasi AM, et al. Treatment of psoriatic arthritis with anti-TNF agents: a systematic review and meta-analysis of efficacy, effectiveness and safety. Rheumatol Int. 2014;34:1345–60.

    Article  CAS  PubMed  Google Scholar 

  21. Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):644–59.

    Article  CAS  PubMed  Google Scholar 

  22. Oussalah A, Danese S, Peyrin-Biroulet L. Efficacy of TNF antagonists beyond one year in adult and pediatric inflammatory bowel diseases: a systematic review. Curr Drug Targets. 2010;11(2):156–75.

    Article  CAS  PubMed  Google Scholar 

  23. Yamauchi PS, Bissonnette R, Teixeira HD, Valdecantos WC. Systematic review of efficacy of anti-tumor necrosis factor (TNF) therapy in patients with psoriasis previously treated with a different anti-TNF agent. J Am Acad Dermatol. 2016;75(3):612–18.e6. https://doi.org/10.1016/j.jaad.2016.02.1221.

    Article  CAS  PubMed  Google Scholar 

  24. Kimball AB, Okun MM, Williams DA, Gottlieb AB, Papp KA, Zouboulis CC, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375(5):422–34.

    Article  CAS  PubMed  Google Scholar 

  25. Sheppard J, Joshi A, Betts KA, Hudgens S, Tari S, Chen N, et al. Effect of adalimumab on visual functioning in patients with noninfectious intermediate uveitis, posterior uveitis, and panuveitis in the VISUAL-1 and VISUAL-2 trials. JAMA Ophthalmol. 2017;135(6):511–8.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117(2):244–79.

    Article  CAS  PubMed  Google Scholar 

  27. Ueda N, Tsukamoto H, Mitoma H, Ayano M, Tanaka A, Ohta SI, et al. The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factorα. Inflamm Bowel Dis. 2013;19(6):1224–31.

    Article  PubMed  Google Scholar 

  28. Horiuchi T, Mitoma H, Harashima SI, Tsukamoto H, Shimoda T. Transmembrane TNF-α: structure, function and interaction with anti-TNF agents. Rheumatology. 2010;49(7):1215–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Nesbitt A, Fossati G, Bergin M, Stephens P, Stephens S, Foulkes R, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor α agents. Inflamm Bowel Dis. 2007;13(11):1323–32.

    Article  PubMed  Google Scholar 

  30. Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell LJ, Macdonald JK, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;2011(2):CD008794.

    PubMed Central  Google Scholar 

  31. Singh JA, Cameron C, Noorbaloochi S, Cullis T, Tucker M, Christensen R, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet. 2015;386(9990):258–65.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Grijalva CG, Chen L, Delzell E, Baddley JW, Beukelman T, Winthrop KL, et al. Initiation of tumor necrosis factor-αantagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA. 2011;306(21):2331–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Minozzi S, Bonovas S, Lytras T, Pecoraro V, González-Lorenzo M, Bastiampillai AJ, et al. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf. 2016;15:11–34. [cited 2020 Oct 10]. https://www.tandfonline.com/doi/abs/10.1080/14740338.2016.1240783.

    Article  CAS  PubMed  Google Scholar 

  34. Kourbeti IS, Ziakas PD, Mylonakis E. Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: a meta-analysis. Clin Infect Dis. 2014;58(12):1649–57.

    Article  PubMed  Google Scholar 

  35. Galloway JB, Mercer LK, Moseley A, Dixon WG, Ustianowski AP, Helbert M, et al. Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2013;72(2):229–34.

    Article  CAS  PubMed  Google Scholar 

  36. Van Dartel SAA, Fransen J, Kievit W, Flendrie M, Den Broeder AA, Visser H, et al. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Ann Rheum Dis. 2013;72(6):895–900.

    Article  PubMed  Google Scholar 

  37. Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002;46(9):2287–93.

    Article  PubMed  Google Scholar 

  38. Cao BL, Qasem A, Sharp RC, Abdelli LS, Naser SA. Systematic review and meta-analysis on the association of tuberculosis in Crohn’s disease patients treated with tumor necrosis factor-α inhibitors (anti-TNFα). World J Gastroenterol. 2018;24(25):2764–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Ai JW, Zhang S, Ruan QL, Yu YQ, Zhang BY, Liu QH, et al. The risk of tuberculosis in patients with rheumatoid arthritis treated with tumor necrosis factor-α antagonist: a metaanalysis of both randomized controlled trials and registry/cohort studies. J Rheumatol. 2015;42(12):2229–37. [cited 2020 Oct 6]. https://pubmed.ncbi.nlm.nih.gov/26472414/.

    Article  CAS  PubMed  Google Scholar 

  40. Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Bréban M, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French research axed on tolerance of biotherapies registry. Arthritis Rheum. 2009;60(7):1884–94. [cited 2020 Oct 10]. http://doi.wiley.com/10.1002/art.24632.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Zhang Z, Fan W, Yang G, Xu Z, Wang J, Cheng Q, et al. Risk of tuberculosis in patients treated with TNF-α antagonists: a systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2017;7(3):e012567.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Winthrop KL, Chang E, Yamashita S, Iademarco MF, LoBue PA. Nontuberculous mycobacteria infections and anti-tumor necrosis factor-α therapy. Emerg Infect Dis. 2009;15(10):1556–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Winthrop KL, Baxter R, Liu L, Varley CD, Curtis JR, Baddley JW, et al. Mycobacterial diseases and antitumour necrosis factor therapy in USA. Ann Rheum Dis. 2013;72(1):37–42.

    Article  CAS  PubMed  Google Scholar 

  44. Toussi SS, Pan N, Walters HM, Walsh TJ. Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-inhibitors: systematic review of the literature. Clin Infect Dis. 2013;57(9):1318–30.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Osterman MT, Sandborn WJ, Colombel JF, Peyrin-Biroulet L, Robinson AM, Zhou Q, et al. Crohn’s disease activity and concomitant immunosuppressants affect the risk of serious and opportunistic infections in patients treated with adalimumab. Am J Gastroenterol. 2016;111(12):1806–15.

    Article  CAS  PubMed  Google Scholar 

  46. Strangfeld A, Eveslage M, Schneider M, Bergerhausen HJ, Klopsch T, Zink A, et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis. 2011;301(7):737–44.

    Google Scholar 

  47. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis. 2007;66(10):1339–44.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emph. Rheumatology. 2011;50(1):124–31.

    Article  CAS  PubMed  Google Scholar 

  49. Dommasch ED, Abuabara K, Shin DB, Nguyen J, Troxel AB, Gelfand JM. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2011;64(6):1035–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Fouque-Aubert A, Jette-Paulin L, Combescure C, Basch A, Tebib J, Gossec L. Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta-analysis of randomised placebo-controlled trials. Ann Rheum Dis. 2010;69(10):1756–61.

    Article  CAS  PubMed  Google Scholar 

  51. Bonovas S, Fiorino G, Allocca M, Lytras T, Nikolopoulos GK, Peyrin-Biroulet L, et al. Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol. 2016;14(10):1385–97.

    Article  PubMed  Google Scholar 

  52. Zhang D, Xiong B, Li X, Xu T, Yu M. Meta-analysis: serious adverse events in Crohn’s disease patients treated with TNF-alpha inhibitors. Hepato-Gastroenterology. 2013;60(126):1333–42.

    CAS  PubMed  Google Scholar 

  53. Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Ustianowski AP, Helbert M, et al. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2011;70(10):1810–4.

    Article  CAS  PubMed  Google Scholar 

  54. Slifman NR, Gershon SK, Lee JH, Edwards ET, Braun MM. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor α-neutralizing agents. Arthritis Rheum. 2003;48(2):319–24.

    Article  CAS  PubMed  Google Scholar 

  55. Bodro M, Paterson DL. Listeriosis in patients receiving biologic therapies. Eur J Clin Microbiol Infect Dis. 2013;32(9):1225–30.

    Article  CAS  PubMed  Google Scholar 

  56. Peña-Sagredo JL, Hernández MV, Fernandez-Llanio N, Giménez-Ubeda E, Muñoz-Fernandez S, Ortiz A, et al. Listeria monocytogenes infection in patients with rheumatic diseases on TNF-alpha antagonist therapy: the Spanish Study Group experience. Clin Exp Rheumatol. 2008;26(5):854–9.

    PubMed  Google Scholar 

  57. Lanternier F, Tubach F, Ravaud P, Salmon D, Dellamonica P, Bretagne S, et al. Incidence and risk factors of legionella pneumophila pneumonia during anti-tumor necrosis factor therapy: a prospective French study. Chest. 2013;144(3):990–8.

    Article  PubMed  Google Scholar 

  58. Kasahara S, Ando K, Saito K, Sekikawa K, Ito H, Ishikawa T, et al. Lack of tumor necrosis factor alpha induces impaired proliferation of hepatitis B virus-specific cytotoxic T lymphocytes. J Virol. 2003;77(4):2469–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Chyuan IT, Hsu PN. Tumor necrosis factor: the key to hepatitis B viral clearance. Cell Mol Immunol. 2018;15(8):731–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Terrault NA, Lok ASF, Mcmahon BJ, Chang K-M, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance American Association for the Study of Liver Diseases. Hepatology. 2018;67(4):1560–99.

    Article  PubMed  Google Scholar 

  61. Chung SJ, Kim JK, Park MC, Park YB, Lee SK. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-α therapy. J Rheumatol. 2009;36(11):2416–20.

    Article  CAS  PubMed  Google Scholar 

  62. Lan JL, Chen YM, Hsieh TY, Chen YH, Hsieh CW, Chen DY, et al. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. Ann Rheum Dis. 2011;70(10):1719–25.

    Article  CAS  PubMed  Google Scholar 

  63. Pauly MP, Tucker LY, Szpakowski JL, Ready JB, Baer D, Hwang J, et al. Incidence of hepatitis B virus reactivation and hepatotoxicity in patients receiving long-term treatment with tumor necrosis factor antagonists. Clin Gastroenterol Hepatol. 2018;16(12):1964–73.

    Article  CAS  PubMed  Google Scholar 

  64. Lee YH, Bae SC, Song GG. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumour necrosis factor therapy. Clin Exp Rheumatol. 2013;31(1):118–21.

    PubMed  Google Scholar 

  65. Tamori A, Koike T, Goto H, Wakitani S, Tada M, Morikawa H, et al. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. J Gastroenterol. 2011;46(4):556–64.

    Article  CAS  PubMed  Google Scholar 

  66. Barone M, Notarnicola A, Lopalco G, Viggiani MT, Sebastiani F, Covelli M, et al. Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection. Hepatology. 2015;62(1):40–6.

    Article  CAS  PubMed  Google Scholar 

  67. Myint A, Tong MJ, Beaven SW. Reactivation of hepatitis B virus: a review of clinical guidelines. Clin Liver Dis. 2020;15(4):162–7.

    Article  Google Scholar 

  68. Lopetuso LR, Mocci G, Marzo M, D’aversa F, Rapaccini GL, Guidi L, et al. Harmful effects and potential benefits of anti-tumor necrosis factor (TNF)-α on the liver. Int J Mol Sci. 2018;19(8):2199.

    Article  PubMed Central  Google Scholar 

  69. Iannone F, La Montagna G, Bagnato G, Gremese E, Giardina A, Lapadula G. Safety of etanercept and methotrexate in patients with rheumatoid arthritis and hepatitis C virus infection: a multicenter randomized clinical trial. J Rheumatol. 2014;41(2):286–92.

    Article  CAS  PubMed  Google Scholar 

  70. Pompili M, Biolato M, Miele L, Grieco A. Tumor necrosis factor-α inhibitors and chronic hepatitis C: a comprehensive literature review. World J Gastroenterol. 2013;19(44):7867–73.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Winthrop KL, Baddley JW, Chen L, Liu L, Grijalva CG, Delzell E, et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA. 2013;309(9):887–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-α agents. JAMA. 2009;301(7):737–44.

    Article  CAS  PubMed  Google Scholar 

  73. Serac G, Tubach F, Mariette X, Salmon-Céron D, Ravaud P, Lioté F, et al. Risk of herpes zoster in patients receiving anti-TNF-α in the prospective French RATIO registry. J Invest Dermatol. 2012;132(3):726–9.

    Article  CAS  PubMed  Google Scholar 

  74. García-Doval I, Pérez-Zafrilla B, Descalzo MÁ, Roselló R, Hernández MV, Gómez-Reino JJ, et al. Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists. Ann Rheum Dis. 2010;69(10):1751–5.

    Article  PubMed  Google Scholar 

  75. Liao TL, Chen YM, Liu HJ, Chen DY. Risk and severity of herpes zoster in patients with rheumatoid arthritis receiving different immunosuppressive medications: a case-control study in Asia. BMJ Open. 2017;7(1):e014032.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Shalom G, Naldi L, Lebwohl M, Nikkels A, de Jong EMGJ, Fakharzadeh S, et al. Biological treatment for psoriasis and the risk of herpes zoster: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Dermatolog Treat. 2019;30(6):534–9.

    Article  CAS  PubMed  Google Scholar 

  77. Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang S-J, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087–96.

    Article  PubMed  Google Scholar 

  78. Dagnew AF, Rausch D, Hervé C, Zahaf T, Levin MJ, Schuind A. Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials. Rheumatology. 2021;60:1226–33.

    Article  PubMed  Google Scholar 

  79. Dooling KL, Guo A, Patel M, Lee GM, Moore K, Belongia EA, et al. Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines. MMWR Morb Mortal Wkly Rep. 2018;67(3):103–8. [cited 2021 May 10]. http://www.cdc.gov/mmwr/volumes/67/wr/mm6703a5.htm?s_cid=mm6703a5_w.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, Van Assen S, Bijl M, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(1):39–52.

    Article  CAS  PubMed  Google Scholar 

  81. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271–84.

    Article  CAS  PubMed  Google Scholar 

  82. Schmader KE, Levin MJ, Gnann JW, McNeil SA, Vesikari T, Betts RF, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis. 2012;54(7):922–8.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Filler SG, Yeaman MR, Sheppard DC. Tumor necrosis factor inhibition and invasive fungal infections. Clin Infect Dis. 2005;41(Suppl 3):S208–12.

    Article  CAS  PubMed  Google Scholar 

  84. Vergidis P, Avery RK, Wheat LJ, Dotson JL, Assi MA, Antoun SA, et al. Histoplasmosis complicating tumor necrosis factor-α blocker therapy: a retrospective analysis of 98 cases. Clin Infect Dis. 2015;61(3):409–17.

    Article  PubMed  PubMed Central  Google Scholar 

  85. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004;38(9):1261–5.

    Article  CAS  PubMed  Google Scholar 

  86. Kaur N, Mahl TC. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci. 2007;52(6):1481–4.

    Article  CAS  PubMed  Google Scholar 

  87. Harigai M, Koike R, Miyasaka N. Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med. 2007;357(18):1874–6.

    Article  CAS  PubMed  Google Scholar 

  88. Warris A, Bjørneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med. 2001;344(14):1099–100.

    Article  CAS  PubMed  Google Scholar 

  89. Baddley JW, Winthrop KL, Chen L, Liu L, Grijalva CG, Delzell E, et al. Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety assessment of biologic ThERapy (SABER) study. Ann Rheum Dis. 2014;73(11):1942–8.

    Article  CAS  PubMed  Google Scholar 

  90. Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP. Fungal infections complicating tumor necrosis factor α blockade therapy. Mayo Clin Proc. 2008;83(2):181–94.

    Article  CAS  PubMed  Google Scholar 

  91. Wallis RS, Broder M, Wong J, Lee A, Hoq L. Reactivation of latent granulomatous infections by infliximab. Clin Infect Dis. 2005;41(Suppl 3):S194–8.

    Article  CAS  PubMed  Google Scholar 

  92. Bergstrom L, Yocum DE, Ampel NM, Villanueva I, Lisse J, Gluck O, et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor α antagonists. Arthritis Rheum. 2004;50(6):1956–66.

    Article  Google Scholar 

  93. Taroumian S, Knowles SL, Lisse JR, Yanes J, Ampel NM, Vaz A, et al. Management of coccidioidomycosis in patients receiving biologic response modifiers or disease-modifying antirheumatic drugs. Arthritis Care Res. 2012;64(12):1903–9.

    Article  CAS  Google Scholar 

  94. Olson TC, Bongartz T, Crowson CS, Roberts GD, Orenstein R, Matteson EL. Histoplasmosis infection in patients with rheumatoid arthritis, 1998-2009. BMC Infect Dis. 2011;11:145.

    Article  PubMed  PubMed Central  Google Scholar 

  95. Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67(2):189–94.

    Article  CAS  PubMed  Google Scholar 

  96. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DPM. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006;54(8):2368–76.

    Article  CAS  PubMed  Google Scholar 

  97. Louie GH, Wang Z, Ward MM. Trends in hospitalizations for Pneumocystis jiroveci pneumonia among patients with rheumatoid arthritis in the US: 1996-2007. Arthritis Care Res. 2010;62(12):3826–7.

    Article  Google Scholar 

  98. Ferri C, Ferraccioli G, Ferrari D, Galeazzi M, Lapadula G, Montecucco C, et al. Safety of anti-tumor necrosis factor-α therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol. 2008;35(10):1944–9.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Infectious Diseases, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA

    Joel V. Chua & John W. Baddley

Authors
  1. Joel V. Chua
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John W. Baddley
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John W. Baddley .

Editor information

Editors and Affiliations

  1. Division of Infectious Diseases, University of Alberta, Edmonton, AB, Canada

    Carlos Cervera

  2. Complutense University of Madrid, University Hospital “October 12”, Madrid, Madrid, Spain

    Jose Maria Aguado

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Chua, J.V., Baddley, J.W. (2022). Anti-tumor Necrosis Factor-Alpha Agents. In: Cervera, C., Aguado, J.M. (eds) Infectious Complications in Biologic and Targeted Therapies. Springer, Cham. https://doi.org/10.1007/978-3-031-11363-5_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-11363-5_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-11362-8

  • Online ISBN: 978-3-031-11363-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation